Lua Labs Report — Iodine Deficiency in LATAM and Hormonal Consequences

Date: 2026-06-08 Researcher: Lua Labs Classification: Nutrigenomics + Neuroendocrine Line: L3 — Thyroid Axis and Reproductive Function Subtopic: 3.5 — Iodine deficiency in LATAM and hormonal consequences: regional data

External Sources

Pretell EA, Pearce EN. (2024). "A history of the elimination of iodine deficiency disorders in the Americas: a dramatic achievement and lessons learned." The Journal of Nutrition, 154(12), 3856-3867. DOI: 10.1016/j.tjnut.2024.10.009. URL: https://jn.nutrition.org/article/S0022-3166(24)01076-9/fulltext
Iodine Global Network. (2025). "Global scorecard of iodine nutrition in 2025 in the general population based on school-age children (SAC)." IGN, updated 22 April 2025. URL: https://ign.org/app/uploads/2025/10/Scorecard_2025_FINAL_22-April-2025.pdf
Candido AC, Azevedo FM, Ribeiro SAV, Navarro AM, Macedo MdS, Fontes EAF, et al. (2025). "Iodine Deficiency and Excess in Brazilian Pregnant Women: A Multicenter Cross-Sectional Study (EMDI-Brazil)." Nutrients, 17(17), 2753. DOI: 10.3390/nu17172753. URL: https://www.mdpi.com/2072-6643/17/17/2753
Silva DLF, Crispim SP, Silva GB, Azevedo FM, de Novaes JF, de Carvalho CA, et al. (2024). "Iodine Intake and its Interindividual Variability in Brazilian Pregnant Women: EMDI Brazil Study." Biological Trace Element Research, 202(7), 3025-3036. DOI: 10.1007/s12011-023-03909-4. PMID: 37874447.
Beer RJ, Herrán OF, Villamor E. (2021). "Median Urinary Iodine Concentration in Colombian Children and Women is High and Related to Sociodemographic and Geographic Characteristics: Results from a Nationally Representative Survey." The Journal of Nutrition, 151(4), 940-948. DOI: 10.1093/jn/nxaa392.
Mills JL, Buck Louis GM, Kannan K, Weck J, Wan Y, Maisog J, Giannakou A, Wu Q, Sundaram R. (2018). "Delayed conception in women with low-urinary iodine concentrations: a population-based prospective cohort study." Human Reproduction, 33(3), 426-433. DOI: 10.1093/humrep/dex379.
Opazo MC, et al. (2026). "Iodine Intake Based on a Survey from a Cohort of Women at Their Third Trimester of Pregnancy from the Bosque County Chile." University of Chile repository. URL: https://repositorio.uchile.cl/bitstream/handle/2250/197307/Iodine-intake.pdf

Base Knowledge (what I know before searching)

Iodine is not a generic "thyroid mineral": it is the structural atom that makes T4 and T3 possible. The thyroid captures circulating iodide through NIS/SLC5A5, oxidizes it in the colloid through TPO using H2O2 generated by DUOX2/DUOXA2, organifies it onto tyrosine residues in thyroglobulin (TG) to form MIT and DIT, and then couples DIT+DIT → T4 and MIT+DIT → T3. This system depends on three classes of inputs: iodine as substrate, selenium as a cofactor for deiodinases/GPx, and immune integrity so TPO/TG do not become autoimmune targets.

The reproductive axis depends on that input at multiple levels. T4/T3 sustain granulosa-theca steroidogenesis, sensitivity to FSH, CYP19A1 expression, luteal function through StAR/CYP11A1/HSD3B, endometrial receptivity through HOXA10/LIF/integrins, and the metabolic modulation of insulin/SHBG described in L3.4. For this reason, mild iodine deficiency does not need to produce clinical hypothyroidism in order to alter reproduction: it can reduce the T4→T3 conversion margin precisely in tissues with high demand, especially the corpus luteum, endometrium, and early pregnancy.

The relationship is not linear. Excess iodine activates the Wolff-Chaikoff effect: the thyroid transiently blocks organification to protect itself. Most people "escape" the block by reducing NIS, but women with subclinical Hashimoto's, TPOAb+, nodularity, postpartum status, or genetic susceptibility can remain trapped in hypo- or hyper-dysfunction. For this reason LATAM should not be understood as "more iodine is always better"; the real target is iodine homeostasis, not maximization.

Before searching, my expectation was: (1) LATAM largely resolved population deficiency through universal salt iodization; (2) pregnant women and women with low access remain vulnerable because requirements rise and school-age data do not represent them; (3) countries with highly iodized salt and high salt consumption probably face excess, not deficiency; (4) the urban transition toward gourmet/non-iodized salt and "clean" diets may create a new deficiency phenotype in middle-class women that classic surveillance does not capture.

Findings From Recent Papers

Pretell & Pearce 2024 reframe the historical context: the elimination of iodine deficiency disorders in the Americas was a genuine public-health achievement. The paper reports that 92% of households in Latin America consume adequately iodized salt and that urinary iodine concentrations in school-age children reflect optimal nutrition at the regional scale. But it also emphasizes two key limitations: surveillance in school-age children does not guarantee sufficiency in pregnant women, and iodization programs must be harmonized with cardiovascular sodium reduction. This reframes L3.5: this is not a simple "LATAM has deficiency" narrative but a system of narrow balance among deficiency, sufficiency, and excess.

The IGN Scorecard 2025 confirms regional heterogeneity. Selected LATAM data: Argentina 117 µg/L (subnational, school-age children, adequate), Brazil 277 (national, school-age children, adequate), Chile 201 (national, adults, adequate), Colombia 407 (national, school-age children, excessive), Costa Rica 314 (national, school-age children, excessive), Ecuador 215 (adequate), Guatemala 171 (adequate), Mexico 297 (subnational, school-age children, adequate), Paraguay 294 (adequate), Peru 292 (adequate), Uruguay 248 (adequate), Venezuela 180 (adequate), but Haiti 77 µg/L in women 15-49 and Nicaragua 90 µg/L in non-pregnant/non-lactating women 14-75 appear as insufficient. This table shows that the "LATAM average" is a poor predictor of individual risk.

EMDI-Brazil 2025 is the most important paper for this report because it studies the physiologically correct group: pregnant women. In 1,891 Brazilian pregnant women with available UIC, the median was adequate (186.7 µg/L), but the distribution was unstable: 36.7% deficiency, 28.7% above requirement, and 3.6% excess. Non-white women had higher risk of deficiency in the final model (OR 1.83; 95% CI 1.27-2.64). The scientific conclusion is not "Brazil is fine" or "Brazil is doing poorly"; it is within-country polarization. The same program produces median sufficiency, deficiency in vulnerable subgroups, and excess in others.

Silva et al. 2024, within EMDI, quantifies iodine sources in Brazilian pregnant women. Mean usual intake was 163.1 µg/day, and the groups that contributed most were condiments/spices, cereals, and dairy; the foods that most explained variability included salt, French bread, whole milk, and rice. The scientific reading is that regional iodine does not enter solely through "seafood" or "table salt": it enters through daily dietary architecture, processing, and staple foods. Distinguishing iodized from non-iodized salt, bread, dairy, egg, and fish approximates iodine exposure better than an isolated question.

Colombia represents the other extreme. Beer et al. 2021 reported high mUIC in children and women of reproductive age using national data; IGN 2025 summarizes Colombia with mUIC 407 µg/L in school-age children, classified as excessive. Later studies in Colombia have associated high ioduria with anti-TPO in school-age subpopulations. This connects directly with L3.3: if iodine excess increases TPO/TG antigenicity through greater thyroglobulin iodination, oxidative stress, and thyroid apoptosis, then a public policy that solved goiter may be creating autoimmune pressure in susceptible people.

The Mills et al. 2018 paper is not LATAM, but it is the best human preconception reproductive anchor: in 467 women trying to conceive, 44.3% were in the deficiency range; the group with iodine/creatinine <50 µg/g had 46% lower fecundability per cycle (adjusted FOR 0.54; 95% CI 0.31-0.94). This does not prove causality or define an intervention, but it does validate that iodine input can affect time to pregnancy before overt thyroid disease appears.

Complete Molecular/Endocrine Mechanism

Iodine enters the L3 continuum as an environmental limiting substrate. L3.1-L3.4 described the signaling: TSHR in ovary/endometrium, tissue DIO2, corpus luteum, anti-TPO, IR/PCOS. L3.5 adds the prior question: is there enough material to manufacture T4/T3 and sustain those nodes?

Dietary iodide
  ↓ intestinal absorption
Plasma I- → NIS/SLC5A5 in thyroid
  ↓
TPO + DUOX2/H2O2 organify iodine onto TG
  ↓
MIT + DIT → T3
DIT + DIT → T4
  ↓
Circulating T4 → DIO2/DIO1 → tissue T3
  ↓
TRα/TRβ in granulosa, corpus luteum, endometrium, liver
  ↓
CYP19A1 + StAR/CYP11A1/HSD3B + HOXA10/LIF + SHBG/GLUT4
  ↓
Ovulation, luteal progesterone, receptivity, insulin sensitivity

The critical point is that the system has a functional reserve. A woman can have "normal" TSH if the pituitary compensates, but if iodine intake drops exactly when requirements rise — luteal phase with corpus luteum demand, early pregnancy, lactation, perimenopause with stress/inflammation — peripheral tissue may lose local T3 before the standard panel becomes pathological. This is especially plausible in women with DIO2 Thr92Ala, diurnal cortisol phenotype=A (high cortisol that ubiquitinates DIO2), or anti-TPO+.

Mild iodine deficiency
  ↓
Marginal T4 output ↓
  ↓
Compensatory TSH ↑ (sometimes within range)
  ↓
If DIO2 works: tissue T3 temporarily preserved
If DIO2 is low (cortisol/DIO2 Ala/Ala/inflammation): ovarian/endometrial T3 ↓
  ↓
Granulosa: response of CYP19A1 to FSH ↓
Corpus luteum: StAR/CYP11A1/HSD3B ↓
Endometrium: HOXA10/LIF/integrins ↓
  ↓
Phenotype: irregular cycle, spotting, high luteal-thyroid phenotype, functional subfertility

Excess operates through a different pathway and connects with L3.3:

Sustained iodine excess
  ↓
TPO generates more reactive species during organification
  ↓
More iodinated Tg + thyroid oxidative stress
  ↓
Greater TPO/Tg antigenic exposure in susceptible people
  ↓
TPOAb/TgAb ↑ + autoimmune thyroiditis
  ↓
Oscillating T4/T3 output or SCH
  ↓
thyroid-autoimmune phenotype ↑ + luteal-thyroid phenotype ↑ + metabolic-reproductive phenotype-T ↑

Therefore, L3.5 does not add an isolated "nutrition branch." It adds an input modulator that can push the whole Thyroid-Reproductive Dysfunction Continuum toward two poles: substrate deficit (hypofunction) or immunogenic excess (autoimmunity/oscillating hyper-hypo).

Cross-Synthesis With Prior Findings

L3.1 TSH as a cycle/endometrium modulator: iodine defines how much effort TSH must make to sustain T4/T3. In mild deficiency, TSH can rise within range and still generate the high thyroid-symptom phenotype. In excess, TSH can fluctuate through Wolff-Chaikoff/escape, generating inconsistent symptoms that look like "strange perimenopause."
L3.2 subclinical hypothyroidism and luteal phase: iodine deficiency lowers the T4 margin available for luteal DIO2. If the corpus luteum is already compromised by cortisol (L2.3) or low progesteroboloma (L1.2), low iodine can be the fourth hit that turns ovulation into insufficient luteal phase.
L3.3 anti-TPO and functional ovarian aging: iodine excess is not benign in AIT. Higher organification can increase thyroid oxidative stress and TPO/TG antigenicity. This suggests that in Colombia/Costa Rica or Brazilian subgroups with high ioduria, the relevant risk is not deficiency but excess-amplified thyroid-autoimmune phenotype.
L3.4 SCH-IR-PCOS/metabolic-reproductive phenotype triangle: IR and central obesity alter deiodinases, leptin-TRH, and SHBG. If insufficient iodine is added to this, the high-metabolic-reproductive phenotype woman enters "triple limitation": low substrate + low conversion + high metabolic demand. If excess is added, the dominant pathway may be autoimmune-metabolic.
L1.4/L1.5 LATAM diet: the traditional Mesoamerican diet is not a strong primary iodine source unless it uses iodized salt, dairy/egg/fish, or fortified products. Migration toward artisanal sea salt, pink salt, "unrefined" salt, or low-sodium diets can silently break iodine input even if the ancestral pattern is favorable for microbiome/ERβ.
L4.1 chronobiology: TSH has a nocturnal pulse. Late meals, irregular sleep, and nighttime cortisol can alter the interpretation of thyroid symptoms. L3.5 suggests that iodine status should not be read in isolation but in interaction with circadian rhythms and the sleep-cortisol pattern.

Lua Labs Hypotheses

Hypothesis 26: "Iodine volatility as a hidden modulator of the LATAM thyroid-reproductive continuum"

Statement: In LATAM women, iodine-associated hormonal risk is not determined by living in a "sufficient" or "deficient" country, but by an individual deficiency-excess volatility signature derived from salt used, salty ultra-processed foods, dairy/bread/egg/fish, pregnancy/lactation, hormonal stage, and autoimmune susceptibility; this signature modulates thyroid-symptom phenotype, luteal-thyroid phenotype, thyroid-autoimmune phenotype, and metabolic-reproductive phenotype independently of age and BMI.

Proposed mechanism: The system has two damage pathways:

Functional deficiency pathway: non-iodized/gourmet salt + low intake of dairy/egg/fish + "clean" diet low in salty ultra-processed foods + pregnancy/lactation/perimenopause → low available iodine → marginal T4 → insufficient tissue T3 if DIO2 is limited by cortisol, inflammation, or DIO2 Ala/Ala → luteal-thyroid phenotype and thyroid-symptom phenotype rise.
Immunogenic excess pathway: highly iodized salt + high load of salty ultra-processed foods + iodized broths/seasonings + country/subregion with high mUIC → high organification → thyroid oxidative stress + greater TPO/TG antigenicity → thyroid-autoimmune phenotype rises, especially with family history of Hashimoto's/POI/PCOS.

The original hypothesis is that both pathways can exist in the same city and the same socioeconomic segment, but through opposite food patterns: "wellness low-salt/no-iodine" vs "high-iodine ultra-processed." The national average cancels them statistically and that is why they do not appear in classic surveillance.

Confidence level: Medium-High. High evidence for iodine-thyroid physiology; high evidence for regional heterogeneity (IGN, EMDI, Colombia); medium evidence for fecundability; low-to-medium evidence for discriminating the individual signature without UIC. What is original is the deficiency-excess volatility framing as an individual variable, not the national average.

How to validate:

With a formal study: n=120 LATAM women aged 18-49, 90 days, stratified into three exposure groups (low-substrate, stable, high-excess) by salt and dietary pattern. Measure spot UIC on 3 non-consecutive days, TSH/fT4/fT3/Tg/anti-TPO, and optional ferritin/selenium. Prediction: the low-substrate group will have lower UIC and greater luteal-thyroid symptom load; the high-excess group will have high UIC and greater anti-TPO positivity, especially with autoimmune family history.

Limitations: UIC has high intraindividual variability; it requires repeated samples. The iodine content in processed foods and dairy products varies by country, season, and industry. A typical dietary diary may omit salt added during cooking or salt brand. The excess-iodine-autoimmunity relationship depends on genetic/immune susceptibility; it should not be communicated as universally causal.

Hypothesis 27: "The wellness-no-iodine phenotype in urban LATAM women"

Statement: Urban LATAM women who migrate from common iodized salt to sea/pink/non-iodized salt, reduce salty ultra-processed foods, and consume little dairy/egg/fish may develop functionally low iodine despite living in countries classified as sufficient.

Proposed mechanism: Regional surveillance relies on school-age children and universal salt. But the "wellness" pattern breaks both premises: lower total salt, non-iodized salt, low milk, low fortified food, possible plant-forward diet, and in some cases pregnancy/lactation. If substrate drops, the axis compensates with TSH. In a woman with diurnal cortisol phenotype=A or vulnerable DIO2, that compensation does not preserve ovarian/endometrial T3. The visible phenotype would be morning fatigue, coldness, constipation, dry skin/hair loss, more variable cycle, spotting, and disproportionate luteal symptoms.

Confidence level: Medium. Mechanistically very plausible and consistent with data on food sources; no specific LATAM cohort yet.

How to validate:

With a formal study: a sub-study of n=60 urban women with a low-iodine-substrate profile; repeat UIC 3 times plus Tg and TSH/fT4/fT3. Confirm whether the exposure pattern predicts low UIC or elevated Tg.

Limitations: Not all sea salt is non-iodized; brands vary. Some women compensate with dairy, egg, fish, or prenatals. The score requires a local database by country.

Hypothesis 28: "Iodized excess as a silent amplifier of thyroid-autoimmune phenotype in LATAM subregions"

Statement: In LATAM countries or subregions with high population ioduria, women with autoimmune family history or elevated thyroid-autoimmune phenotype will be more likely to have positive anti-TPO and fluctuating thyroid symptoms than women with stable exposure, even if they are not deficient.

Proposed mechanism: High iodine increases the organification load through TPO and may raise thyroid oxidative stress. In an immune-susceptible person, this exposes TPO/TG epitopes, activates local antigen presentation, and facilitates TPOAb/TgAb. In L3.3 we saw that AIT can accelerate functional ovarian aging and damage luteal phase. Here the environmental input is iodized excess, not deficiency.

Confidence level: Medium. Strong evidence for U-shaped iodine-thyroid risk; regional evidence of excess in Colombia/Costa Rica; lack of longitudinal demonstration in reproductive-age LATAM women.

How to validate:

With a formal study: n=100 in high-iodine subregion vs n=100 in adequate subregion; measure repeated UIC, anti-TPO/TgAb, Tg, TSH/fT4. Prediction: high exposure × family history interaction increases odds of anti-TPO+.

Limitations: Population excess in school-age children does not necessarily represent adult women. High UIC does not prove chronic individual exposure. Autoimmunity requires predisposition and may precede the exposure.

Candidate Formulation (if applicable)

I do not propose a compound formulation for L3.5. In iodine, a candidate formulation without biomarkers can be scientifically irresponsible because deficiency and excess share symptoms and both can damage the thyroid axis. The research output is not "add iodine"; it is stratify exposure.

Non-therapeutic candidate: an iodine exposure mapping oriented toward stratification, not supplementation.

Components: salt type, frequency of salt use at home, table salt vs cooking salt, consumption of dairy/egg/fish/bread/salty ultra-processed foods/broths, pregnancy/lactation, prenatal supplements with iodine (self-report), and personal/family thyroid history.

Target population: reproductive-age women with irregular cycles or fatigue; women in perimenopausal transition with perimenopause-thyroid overlap; and, in older women, only as educational support for the medical conversation, due to higher prevalence of thyroid pathology and nodularity.

Status: education and research-based exposure stratification; no diagnosis, no prescription.

Requires validation: correlation between the estimated exposure pattern and UIC/Tg/TSH/anti-TPO in a formal sub-study before using it as a screening tool.

Individual Variability

The same iodine exposure does not produce the same effect because of at least eight modulators:

Thyroid autoimmunity: anti-TPO/TgAb changes the damage threshold from excess.
DIO2 Thr92Ala: reduces T4→T3 conversion resilience when T4 is marginal.
Selenium: cofactor for deiodinases and glutathione peroxidase; selenium deficiency makes the TPO process more oxidative.
Iron: TPO is a hemoprotein; low ferritin can worsen thyroid synthesis even with adequate iodine.
Pregnancy/lactation: increases requirement and renal/milk loss.
Salt pattern: iodized vs non-iodized matters more than "total salt"; ultra-processed foods may provide iodized salt or not depending on industry.
Geography/soil/water: Andes, rural areas, islands, coasts, and cities differ; country is not enough.
Microbiome and diet: affects absorption, enterohepatic circulation of thyroid hormones, and cofactors.